Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.
about
Treatment of relapsed and refractory multiple myelomaCurrent and emerging treatment options for patients with relapsed myelomaInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationNKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple MyelomaProof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myelomaA phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.Short-course bortezomib-based retreatment for patients with multiple myeloma who had received bortezomib-thalidomide-dexamethasone (VTD) as an initial therapy: A single-center case series.Modified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myeloma.Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patients.Clinical outcome of bortezomib retreatment in patients with relapsed or refractory multiple myeloma.Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma.Synthesis of Lithocholic Acid Derivatives as Proteasome RegulatorsEfficient allocation of novel agents in multiple myeloma: a work in progressPSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma.Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaImpact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR studyCarfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.SIAH proteins: critical roles in leukemogenesis.Current approaches for the treatment of multiple myeloma.Choosing treatment options for patients with relapsed/refractory multiple myeloma.B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies.New approaches to management of multiple myeloma.Transcription factor IKZF1 is degraded during the apoptosis of multiple myeloma cells induced by kinase inhibition.Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.Developing a Novel Indolocarbazole as Histone Deacetylases Inhibitor against Leukemia Cell Lines.Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients.Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.1,2,3,4,6-Penta-O-Galloyl-Beta-D-Glucopyranoside Inhibits Proliferation of Multiple Myeloma Cells Accompanied with Suppression of MYC Expression.
P2860
Q26749180-D2FE9116-D5CE-46CE-9270-DE3822C7BEB0Q26830878-90232F0D-AB5E-4540-BDAD-02EDF1406744Q27002668-E2DDDE9E-DDC4-48FA-84BE-938EAA4D2FEDQ28080823-F8A61A68-C1FB-405D-AEFD-7F2177E17CC4Q28537857-89504FE3-B165-4956-811A-CD3A744E12A7Q33402536-335B4AC7-621A-43A4-B388-F0F0D4C37FFDQ33409681-32BC8BAD-6610-41E9-92F5-076CB5383494Q33411708-750A4587-FE77-4D19-8BCF-6617E17D1A7EQ33414211-AB18EA69-BC42-4DF0-A2EB-265031C49226Q33415992-4CD0700E-A82D-446D-9A42-C3F28A95AD05Q33418300-6D3168D3-2769-4DD2-9144-8739E5AC136FQ33419442-F67C1F02-4906-4720-A4CC-AE77AB597127Q33437691-2C64B7DA-6623-42D9-A093-B41930E3809DQ34291281-9EBB8F36-8810-4AFD-A1BD-6C7880B253BAQ35546925-B925320F-6D23-44F6-900C-75A2A6B7A204Q35809982-DC4C21DB-B43F-406D-A1C0-6025353DC377Q36520715-A0CD0D74-A379-4344-9055-1343E806049CQ36529762-19CFBE17-D308-4053-A039-D01CC3C60CF5Q36565638-8CEF39F2-19B3-469D-AB16-33E2FE5CA1BAQ36839558-201B401B-6BF2-44D1-B6DD-BF04C51DEADEQ37171994-A82F0D0F-C949-4C58-8B56-030DBA2D1F35Q37570630-E54ACB1B-739F-4217-919F-BB45F4BF1DEBQ37735651-BCC0CAE9-4480-4AFC-81B4-316EF67126B0Q38049544-31AB74D1-53A9-4385-862F-B5D01749DDBEQ38087939-CCF08FBA-191C-47FC-8717-C997CD5E8598Q38170453-0E74F8C1-7E08-40EA-BB03-13E9895C8940Q38185363-BE96955C-F371-4EAD-94A4-BC630193ED30Q38191867-800A6F00-BCBE-444A-99F2-AE8634A49769Q38852158-8CE1981B-3460-4DA5-90A2-376D7F9A73D9Q39524467-FFA1AD21-A4D8-45A6-8C2F-84E1E03CE7CCQ39690253-68988967-A467-443A-88E4-E470E9BBEA4BQ41065264-8C641E49-3FC2-45BB-8B12-BFB2A00271E2Q41245046-7F76B413-19CB-42AA-857A-B17386D4BB60Q44559311-D6352CE4-BAD1-478C-AF47-212E23644C47Q47348957-8D310043-0A97-48E7-A9B9-0C30D18513B1Q50199534-4BBA2D61-856C-4D5A-8856-F8646FF22D58
P2860
Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Treatment strategies in relaps ...... es in the era of novel agents.
@en
Treatment strategies in relaps ...... es in the era of novel agents.
@nl
type
label
Treatment strategies in relaps ...... es in the era of novel agents.
@en
Treatment strategies in relaps ...... es in the era of novel agents.
@nl
prefLabel
Treatment strategies in relaps ...... es in the era of novel agents.
@en
Treatment strategies in relaps ...... es in the era of novel agents.
@nl
P2093
P2860
P356
P1433
P1476
Treatment strategies in relaps ...... hes in the era of novel agents
@en
P2093
P2860
P2888
P356
10.1038/LEU.2011.310
P577
2011-10-25T00:00:00Z